Portfolio exits Kurma Partners recently sold assets to Charles River Laboratories, highlighting a successful exit track record and potential interest in strategic buyers or co-investors for portfolio assets.

Biotech focus With dedicated franchises Kurma Biofund and Kurma Diagnostics, the firm specializes in therapeutics and diagnostic/digital health, presenting opportunities to align with clinical-stage startups and contract development organizations seeking funding or partnerships.

Active fundraising Recent fundraisings and first closings such as Biofund IV indicate ongoing capital deployment in healthcare ventures, suggesting readiness for co-investments, side letters, or fund-of-funds collaboration.

Recent wins Notable investments in Memo Therapeutics, Alveus Therapeutics, Nuclidium, Raidium, and SciRhom demonstrate an appetite for early-to-mid stage biotech and radiopharmaceutical platforms, signaling potential for follow-on funding rounds or strategic alliances.

European footprint As a Paris-based European VC with a multi-portfolio healthcare focus and significant activity across startups in Europe and the US, Kurma Partners offers cross-border collaboration opportunities, co-investments, and distribution or commercialization partnerships for portfolio companies.